Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
Fiche publication
Date publication
juillet 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Daniele B, Croitoru A, Papandreou C, Bronowicki JP, Mathurin P, Serejo F, Stal P, Turnes J, Ratziu V, Bodoky G
Lien Pubmed
Résumé
SUMMARY Aims: To evaluate sorafenib dosing and safety in the Global Investigation of therapeutic GIDEON study's European subpopulation. PATIENTS & METHODS: Patient demographics, disease characteristics and treatment history were recorded at enrollment; dose, adverse events and efficacy were recorded at follow-up. RESULTS: Of 1113 evaluable patients, 82% started on 800 mg/day sorafenib; patients starting on 400 mg/day were slightly older, had baseline characteristics indicative of greater disease progression and higher adverse events incidences (96 vs 88%). Treatment duration (18.0 vs 13.0 weeks) and median overall survival (12.1 vs 9.4 months) were longer in patients receiving 800 mg/day. CONCLUSION: Imbalances in independent predictive factors may have led to longer survival in patients receiving 800 mg/day sorafenib; nonetheless, results suggest that the majority can start on this dose.
Référence
Future Oncol. 2015 Jul 9:1-10.